DoH Policies screened during the period: 1st April 2019 - 30th June 2019 | Department of Health

In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).

Documents

NICE Technology Appraisal TA553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
PDF (107 KB)

NICE Technology Appraisal TA554 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
PDF (66 KB)

NICE Technology Appraisal TA557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
PDF (67 KB)

NICE Technology Appraisal TA558 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
PDF (64 KB)

NICE Technology Appraisal TA540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
PDF (112 KB)

NICE Technology Appraisal TA561 - Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
PDF (107 KB)

Eligibility for HSC-funded IVF and related treatments
PDF (139 KB)

High Level Equality Screening Budget
PDF (112 KB)

The Firefighters’ Pension Scheme (Amendment and Transitional Provisions) Order (Northern Ireland) 2019 – Contribution Holidays
PDF (164 KB)

Help viewing documents